Standard & Poor's Stock Reports Gives Nymox ''Bullish'' Rating.MAYWOOD, N.J. -- Nymox Pharmaceutical Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :NYMX NYMX New York Mercantile Exchange ) received favorable coverage in a new Standard & Poor's Stock Report. The new report on Nymox rates the stock as "bullish" on technical evaluation. The Stock Report was written by S&P analyst Craig C. Pratesi. The new three page report analyzes the company's business activities and stock performance. This new positive report follows on considerable recent positive news from the Company. The Company recently announced that its AlzheimAlert(TM) urine test was advancing to an FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. Advisory Panel meeting. The Company also announced that it had signed marketing and distribution deals for this product in Italy with Alifax S.p.A. and in the Czech Republic with Klinlab Ltd. Nymox announced at the end of 2004 that it had received the European certification CE Mark for its AlzheimAlert(TM) urinary test kit device for the diagnosis of Alzheimer's Disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. . Nymox's TobacAlert(TM) tobacco product exposure and second hand smoke test is carried nationally by CVS (1) (Concurrent Versions System) A version control system for Unix that was initially developed as a series of shell scripts in the mid-1980s. CVS maintains the changes between one source code version and another and stores all the changes in one file. Stores in the U.S., which has over 5400 pharmacy stores throughout the country. Nymox holds U.S. and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's new drug treatment for benign prostatic hyperplasia benign prostatic hyperplasia n. Abbr. BPH A nonmalignant enlargement of the prostate gland commonly occurring in men after the age of 50, and sometimes leading to compression of the urethra and obstruction of the flow of urine. is currently at the stage of large pivotal testing. The Company's products have received numerous positive recommendations in the press. More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 1-800-936-9669. This press release contains certain forward-looking statements as defined in the United States Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion